| Literature DB >> 25012120 |
Linlin Yin1, Yongyan Chen2, Zhao Qu3, Li Zhang4, Qi Wang3, Qi Zhang2, Lin Li5.
Abstract
In the present study, we investigated the therapeutic benefit of cornel iridoid glycoside (CIG), the main component extracted from Cornus officinalis, in experimental autoimmune encephalomyelitis (EAE) rats. CIG was intragastrically administered daily after EAE initiation for 20days and reduced disease severity, incidence, disease onset and ongoing paralysis. Histopathological staining showed that CIG could reduce T cell entry to the central nervous system and microglia activation, increased brain-derived neurotrophic factor (BDNF) expression and mature oligodendrocytes, and decreased oligodendrocyte progenitor cells (OPCs). Also, CIG treatment inhibited brain JAK/STAT1/3 and reduced proinflammatory cytokines. CIG might be a novel potential therapeutic agent for multiple sclerosis (MS).Entities:
Keywords: Cornel iridoid glycoside; Experimental autoimmune encephalomyelitis; JAK/STAT signaling; Multiple sclerosis; Neuroinflammation
Mesh:
Substances:
Year: 2014 PMID: 25012120 DOI: 10.1016/j.jneuroim.2014.06.022
Source DB: PubMed Journal: J Neuroimmunol ISSN: 0165-5728 Impact factor: 3.478